EligibleTrials

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting · NCT07562152 · Interventional (participants receive a specific treatment) · Lead sponsor: Immuneering Corporation

View the official record on ClinicalTrials.gov →
Pancreatic Cancer

Interventions studied

AtebimetinibGnPmGnP

What this trial is about

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

41 locations listed across 23 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.